SWI/SNF-Compromised Cancers Are Susceptible to Bromodomain Inhibitors.
Journal
Cancer research
ISSN: 1538-7445
Titre abrégé: Cancer Res
Pays: United States
ID NLM: 2984705R
Informations de publication
Date de publication:
15 05 2019
15 05 2019
Historique:
received:
18
05
2018
revised:
18
10
2018
accepted:
12
03
2019
pubmed:
17
3
2019
medline:
15
2
2020
entrez:
17
3
2019
Statut:
ppublish
Résumé
The antitumor activity of bromodomain and extraterminal motif protein inhibitors (BETi) has been demonstrated across numerous types of cancer. As such, these inhibitors are currently undergoing widespread clinical evaluation. However, predictive biomarkers allowing the stratification of tumors into responders and nonresponders to BETi are lacking. Here, we showed significant antiproliferative effects of low dosage BETi
Identifiants
pubmed: 30877105
pii: 0008-5472.CAN-18-1545
doi: 10.1158/0008-5472.CAN-18-1545
doi:
Substances chimiques
Biomarkers, Tumor
0
Nuclear Proteins
0
SMARCA2 protein, human
0
Transcription Factors
0
SMARCA4 protein, human
EC 3.6.1.-
DNA Helicases
EC 3.6.4.-
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
2761-2774Subventions
Organisme : CIHR
ID : 399061
Pays : Canada
Organisme : CIHR
ID : 399114
Pays : Canada
Informations de copyright
©2019 American Association for Cancer Research.